Pectin-based nanomaterials as a universal polymer for type 2 diabetes management
Type 2 diabetes mellitus (T2DM) is characterized by insufficient tissue insulin sensitivity, insufficient compensatory insulin secretory response, and insufficient insulin production by pancreatic islet cells, which account for more than 90% of all instances of diabetes mellitus, and defects in any...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Medical Journal of Babylon |
| Subjects: | |
| Online Access: | http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2023;volume=20;issue=1;spage=7;epage=12;aulast=Abdulhakeem |
| _version_ | 1797775433250373632 |
|---|---|
| author | Zahraa Raad Abdulhakeem Atheer Hameid Odda Sura Ahmed Abdulsattar |
| author_facet | Zahraa Raad Abdulhakeem Atheer Hameid Odda Sura Ahmed Abdulsattar |
| author_sort | Zahraa Raad Abdulhakeem |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is characterized by insufficient tissue insulin sensitivity, insufficient compensatory insulin secretory response, and insufficient insulin production by pancreatic islet cells, which account for more than 90% of all instances of diabetes mellitus, and defects in any of the mechanisms at play may cause a metabolic imbalance that results in the development of T2DM. By getting around several delivery limitations, nanomedicine can effectively increase the efficacy of oral drug administration. According to reports, nanostructures are absorbed 15–250 times more readily than microparticles. Furthermore, nanostructures are constantly used to maintain the release of drugs that are encapsulated to lower doses and dosage frequency, improving patient compliance and reducing adverse effects. Pectin is a biocompatible polysaccharide with a natural biological activity, which pectin in rats with type 2 diabetes was discovered to have potent hypoglycemic, antioxidant, immunomodulating, and anticancer properties that improved diabetic conditions and consequences, reduced insulin resistance, improved blood lipid levels, and reduced liver glycogen content, glucose tolerance, and glucose levels. As a result, the purpose of this article was to evaluate the background materials on the current condition of the scientific literature in this field of study and to review the employment feasibility as well as pectin-modified nanomaterial toward T2DM treatment because it has the ability to reduce insulin secretion and/or blood glucose levels following a sugar load. |
| first_indexed | 2024-03-12T22:35:40Z |
| format | Article |
| id | doaj.art-98b0da5887a345dabbe6ae4e32a76b86 |
| institution | Directory Open Access Journal |
| issn | 1812-156X 2312-6760 |
| language | English |
| last_indexed | 2024-03-12T22:35:40Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Medical Journal of Babylon |
| spelling | doaj.art-98b0da5887a345dabbe6ae4e32a76b862023-07-21T12:46:31ZengWolters Kluwer Medknow PublicationsMedical Journal of Babylon1812-156X2312-67602023-01-0120171210.4103/MJBL.MJBL_242_22Pectin-based nanomaterials as a universal polymer for type 2 diabetes managementZahraa Raad AbdulhakeemAtheer Hameid OddaSura Ahmed AbdulsattarType 2 diabetes mellitus (T2DM) is characterized by insufficient tissue insulin sensitivity, insufficient compensatory insulin secretory response, and insufficient insulin production by pancreatic islet cells, which account for more than 90% of all instances of diabetes mellitus, and defects in any of the mechanisms at play may cause a metabolic imbalance that results in the development of T2DM. By getting around several delivery limitations, nanomedicine can effectively increase the efficacy of oral drug administration. According to reports, nanostructures are absorbed 15–250 times more readily than microparticles. Furthermore, nanostructures are constantly used to maintain the release of drugs that are encapsulated to lower doses and dosage frequency, improving patient compliance and reducing adverse effects. Pectin is a biocompatible polysaccharide with a natural biological activity, which pectin in rats with type 2 diabetes was discovered to have potent hypoglycemic, antioxidant, immunomodulating, and anticancer properties that improved diabetic conditions and consequences, reduced insulin resistance, improved blood lipid levels, and reduced liver glycogen content, glucose tolerance, and glucose levels. As a result, the purpose of this article was to evaluate the background materials on the current condition of the scientific literature in this field of study and to review the employment feasibility as well as pectin-modified nanomaterial toward T2DM treatment because it has the ability to reduce insulin secretion and/or blood glucose levels following a sugar load.http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2023;volume=20;issue=1;spage=7;epage=12;aulast=Abdulhakeemapple pomacediabetes mellitus type 2nanomedicinenanoparticlesnanotechnologypectin |
| spellingShingle | Zahraa Raad Abdulhakeem Atheer Hameid Odda Sura Ahmed Abdulsattar Pectin-based nanomaterials as a universal polymer for type 2 diabetes management Medical Journal of Babylon apple pomace diabetes mellitus type 2 nanomedicine nanoparticles nanotechnology pectin |
| title | Pectin-based nanomaterials as a universal polymer for type 2 diabetes management |
| title_full | Pectin-based nanomaterials as a universal polymer for type 2 diabetes management |
| title_fullStr | Pectin-based nanomaterials as a universal polymer for type 2 diabetes management |
| title_full_unstemmed | Pectin-based nanomaterials as a universal polymer for type 2 diabetes management |
| title_short | Pectin-based nanomaterials as a universal polymer for type 2 diabetes management |
| title_sort | pectin based nanomaterials as a universal polymer for type 2 diabetes management |
| topic | apple pomace diabetes mellitus type 2 nanomedicine nanoparticles nanotechnology pectin |
| url | http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2023;volume=20;issue=1;spage=7;epage=12;aulast=Abdulhakeem |
| work_keys_str_mv | AT zahraaraadabdulhakeem pectinbasednanomaterialsasauniversalpolymerfortype2diabetesmanagement AT atheerhameidodda pectinbasednanomaterialsasauniversalpolymerfortype2diabetesmanagement AT suraahmedabdulsattar pectinbasednanomaterialsasauniversalpolymerfortype2diabetesmanagement |